SWOG clinical trial number
S9910

Leukemia Centralized Reference Laboratories and Tissue Repositories, Ancillary

Closed
Phase
Abbreviated Title
Leukemia Repository
Activated
04/15/1999
Closed
01/01/2012
Participants
NCORP, Members, Medical Oncologists, Pathologists, CTSU, Affiliates

Research committees

Leukemia

Eligibility Criteria Expand/Collapse

Patients must be registered on a Southwest Oncology Group leukemia treatment study on or after the date of activation of this study.

Publication Information Expand/Collapse

2016

Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia

Gu Z;M Churchman;K Roberts;Y Li;R Harvey;K McCastlain;S Reshmi;D Payne-Turner;I Iacobucci;Y Shao;IM Chen;M Valentine;D Pei;K Mungall;A Mungall;Y Ma;R Moore;M Marra;E Stonerock;J Gastier-Foster;M Devidas;Y Dai;B Wood;M Borowitz;E Larsen;K Maloney;L Mattano;A Angiolillo;W Salzer;M Burke;F Gianni;O Spinnelli;JP Radich;MD Minden;A Moorman;B Patel;A Fielding;J Rowe;S Luger;R Bhatia;I Aldoss;SJ Forman;J Kohlschmidt;K Mrozek;G Marcucci;C Bloomfield;W Stock;W Kornblau;H Kantarjian;M Konopleva;E Paietta;C Willman;M Loh;S Hunger;C Mullighan Nature Communications Nov 8;7:13331

PMid: PMID27824051 | PMC number: PMC5105166

2012

Impact of residual normal metaphases in core binding factor acute myeloid leukemia

B Medeiros;M Othus;M Fang;F Appelbaum;E Estey Cancer 118(9):2420-2423;

PMid: PMID21928314 | PMC number: PMC3490403

Other Clinical Trials

SWOG Clinical Trial Number
CTSU/A042001

A Randomized Phase II Study Comparing Inotuzumab Plus Chemotherapy Versus Standard Chemotherapy in Older Adults with Philadelphia-Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia
Research Committee(s)
Leukemia
Activated
02/27/2023
Open
Phase
SWOG Clinical Trial Number
S1925

A Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia (CLL): EVOLVE CLL Study.
Research Committee(s)
Leukemia
Lymphoma
Symptom Control and Quality of Life
Activated
12/14/2020
Accrual
49%
Open
Phase
SWOG Clinical Trial Number
CTSU/AALL1821

A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination with Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old with First Relapse
Research Committee(s)
Leukemia
Activated
12/04/2020
Open